Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Skin and Connective Tissue Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Carcinoma

Lung Neoplasms

Adenocarcinoma

Triple Negative Breast Neoplasms

Carcinoma, Renal Cell

Kidney Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Breast Diseases

Skin Diseases

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

All Drugs and Chemicals

Antineoplastic Agents

Anti-Infective Agents

Antibodies

Everolimus

Immunoglobulins

Panobinostat

Spartalizumab

Sirolimus

Temsirolimus

MTOR Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Immunosuppressive Agents

Immunologic Factors

Histone Deacetylase Inhibitors

Immune Checkpoint Inhibitors

Antineoplastic Agents, Immunological

Enrollment to this combination arm is closed to further enrollment.

Dose escalation completed, expansion arm.

PDR001

LCL161

QBM076

HDM201

Novartis Pharmaceuticals

The purpose of this study was to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)

During the first two cycles Cycle = 28 days

Through study completion, an average of 6 months

Baseline and end of treatment, an average of 6 months

Cycle 1 through cycle 6 in treatment period 1, an average of 6 months

Cycle 1 through cycle 6 in treatment period 1 and 2, an average of 6 months

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat	NCT02890069	Colorectal Canc...	PDR001 LCL161 Everolimus Panobinostat QBM076 HDM201	18 Years -	Novartis
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat	NCT02890069	Colorectal Canc...	PDR001 LCL161 Everolimus Panobinostat QBM076 HDM201	18 Years -	Novartis
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat	NCT02890069	Colorectal Canc...	PDR001 LCL161 Everolimus Panobinostat QBM076 HDM201	18 Years -	Novartis

Spots Global Cancer Trial Database for qbm076

Every month we try and update this database with for qbm076 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for qbm076

Every month we try and update this database with for qbm076 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for qbm076 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.